Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2019) 134 (Supplement_1): 580.

https://doi.org/10.1182/blood-2019-128519

Published: 2019

Journal Articles

Preliminary Exploration of Patient Perspectives on Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia

Bradley Mason, Carla M. Mamolo, PhD, Chloe Johnson, Andrea Viqueira, MD, Adam Gater, Alexander Russell-Smith, Sophi Tatlock, Richa Shah, PharmD, RPh, Joseph C Cappelleri, PhD MPH, MS

Blood (2019) 134 (Supplement_1): 5918.

https://doi.org/10.1182/blood-2019-123444

Published: 2019

Journal Articles

The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies

Paul G. Richardson, MD, Joseph Mikhael, MD FRCPC, MD, Thierry Facon, MD, William I. Bensinger, Sandrine Macé, Marielle Chiron, Helgi van de Velde, MD PhD, Frank Campana, MD, Li Liu, Michel Attal, MD PhD

Blood (2019) 134 (Supplement_1): 3179.

https://doi.org/10.1182/blood-2019-128071

Published: 2019

Journal Articles

Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Cyrille Hulin, MD, Paul G. Richardson, MD, Michel Attal, MD PhD, Hugh J. Goodman, FRACP, Vadim A Doronin, MD, Ivan Spicka, MD PhD Prof, Solenn Le-Guennec, Frank Campana, MD, Helgi van de Velde, MD PhD, Meral Beksac, MD

Blood (2019) 134 (Supplement_1): 3185.

https://doi.org/10.1182/blood-2019-129840

Published: 2019

Journal Articles

A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety

Blood (2019) 134 (Supplement_1): 1898.

https://doi.org/10.1182/blood-2019-129103

Published: 2019

Journal Articles

Evaluating Isatuximab Interference with Monoclonal Protein Detection By Immuno-Capture and Liquid Chromatography Coupled to High Resolution Mass Spectrometry in the Pivotal Phase 3 Multiple Myeloma Trial, Icaria-MM

Greg Finn, PhD, Sandrine Macé, Frank Campana, MD, Solenn Le-Guennec, Stephané Muccio, Alexandra Tavernier, Marie-Claude Rouchon, Alain Roccon, Shujia Dai, Valérie Boutet, Dominique Mouret, Béatrice Pradeilles, Sébastien Hugla, Graziella Engelvin, Deborah DiNoto, Helgi van de Velde, MD PhD, Olivier Fedeli

Blood (2019) 134 (Supplement_1): 3143.

https://doi.org/10.1182/blood-2019-129963

Published: 2019

Journal Articles

Potential Overuse of Primary Thromboprophylaxis in Medical Inpatients at Low Risk of Venous Thromboembolism

Mia Djulbegovic, MD, Kevin Chen, MD, Soundari Sureshanand, MCA, Sarwat Chaudhry, MD

Blood (2019) 134 (Supplement_1): 3385.

https://doi.org/10.1182/blood-2019-131827

Published: 2019

Journal Articles

Geriatric Assessment (GA) Measures and Patient-Reported Outcomes (PROs) Among Older Adults Treated in a Phase 1b Study for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Heidi D. Klepin, MD MS, Avrita Campinha-Bacote, Wan-Jen Hong, Patrick Phuong, Jue Wang, Mehrdad Mobasher, MD MPH, Peter Trask

Blood (2018) 132 (Supplement 1): 4076.

https://doi.org/10.1182/blood-2018-99-116038

Published: 2018

Journal Articles

Inotuzumab Ozogamicin Compassionate Use for French Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Charlotte Calvo, Benoit Brethon, Aurelie Cabannes-Hamy, MD, Dalila Adjaoud, MD, Benedicte Bruno, MD, Laurence Blanc, MD, Nicolas Boissel, MD PhD, Marie-Dominique Tabone, MD, Andre Baruchel, MD

Blood (2018) 132 (Supplement 1): 5203.

https://doi.org/10.1182/blood-2018-99-116360

Published: 2018

Journal Articles

Economic Impact of Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Compared to Conventional Recombinant Factor VIII (rFVIII)

Nanxin Li, Koo Wilson, Marc Botteman, MS, MA, Daniel Nicoloso, Sangeeta Krishnan, PharmD, Jun Su, MD

Blood (2018) 132 (Supplement 1): 3520.

https://doi.org/10.1182/blood-2018-99-114993

Published: 2018

Journal Articles

A Patient-Centred Approach to Understanding the Trade-Offs Associated with Treatment Decision Making in Hematological Cancers with Short Life Expectancy

Chloe Johnson, Timothy J Bell, Kate Sully, PhD, Verna L Welch, PhD MPH, CPEHR, CPHIMS, Francois Peloquin, BS, Adam Gater

Blood (2018) 132 (Supplement 1): 5899.

https://doi.org/10.1182/blood-2018-99-116226

Published: 2018

Journal Articles

Obinutuzumab for CLL Relapsed and Refractory Patients When New Oral Drugs an Not Available

Laura Fogliatto, MD, Kamila Grokoski, Ana Segatto, Mirna Philipp, Jorge Vaz Pinto Neto, Eugenio Escovar, Yuri Vasconcelos, MDPhD, Jair Schimidt Filho, Talita Silveira, Tania Hellwig, Christina Fraga

Blood (2017) 130 (Supplement 1): 5341.

https://doi.org/10.1182/blood.V130.Suppl_1.5341.5341

Published: 2017

Journal Articles

Impact on Quality of Life (QoL) of Patients with Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Under Ibrutinib Treatment: Preliminary Data from a Real World Prospective Project (pilot study)

Maria J. Mela Osorio, MD, Carolina Pavlovsky, MD, Mariana Juni, Ms, Isolda I. Fernandez, MD, Luciana C. Ferrari, MD, Esteban Ciliberti, MD, Miguel A. Pavlovsky, MD

Blood (2017) 130 (Supplement 1): 5343.

https://doi.org/10.1182/blood.V130.Suppl_1.5343.5343

Published: 2017

Journal Articles

Patient Perspectives on Symptom Experience and Impact on Health-Related Quality of Life in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia

Jill A Bell, PhD, Aaron Galaznik, MD, Farrah A Pompilus, Sara Strzok, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Patrick Marquis

Blood (2017) 130 (Supplement 1): 3458.

https://doi.org/10.1182/blood.V130.Suppl_1.3458.3458

Published: 2017

Journal Articles

Kinetics of T-Cell Subset Reconstitution Following Bendamustine-Containing Therapy for Low-Grade Lymphoproliferative Disease; A Population Based Analysis

Sarah Hartley, MBBS, MRCP, Amy Beech, Catherine Griffiths, Faith Richardson, Helen Knight, Andrew K. McMillan, FRCP, Mark Bishton, Chris P Fox

Blood (2017) 130 (Supplement 1): 3586.

https://doi.org/10.1182/blood.V130.Suppl_1.3586.3586

Published: 2017

Journal Articles

Novel Lineage Depletion and Manufacturing Allows for Unprecedented Preservation of Autologous Blood Stem Cells for Gene Therapy of Fanconi Anemia Complementation Group Α

Jennifer Adair, PhD, Devikha Chandrasekaran, MS, Stefanie Schmuck, BS, Gabriella Sghia-Hughes, BS, Grace Choi, BS, Anne Lee, BS, Kevin G Haworth, BS, PhD, Ann Woolfrey, MD, Lauri S Burroughs, MD, Pamela S. Becker, MD PhD, Hans-Peter Kiem, MD PhD

Blood (2017) 130 (Supplement 1): 2451.

https://doi.org/10.1182/blood.V130.Suppl_1.2451.2451

Published: 2017

Journal Articles

Laboratory-Developed MLPA ® Probes Enable CNV Detection in the CFHR4 Gene to Aid aHUS Genetic Evaluation

Kevin Pirelli, BS, Curt Czajkowski, BS, MT(ASCP), Veronika Mladenova, BS, Stefanie Dugan, MS, CGC, Valerie Trapp-Stamborski, PhD, Kenneth D Friedman, MD, Rupa A Udani, PhD

Blood (2016) 128 (22): 1361.

https://doi.org/10.1182/blood.V128.22.1361.1361

Published: 2016

Journal Articles

Safety and Efficacy of Blinatumomab Used in Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Treated in French Hematological Centers

Anne-Flore Derache, MD, Fanny Rialland, MD, Gerard Michel, MD, Yves Perel, MD, Virginie Gandemer, MD PhD, Pascale Blouin, MD, Odile Minckes, MD, Arnaud Petit, MD PhD, Andre Baruchel, MD PhD, Benoit Brethon, MD

Blood (2016) 128 (22): 5190.

https://doi.org/10.1182/blood.V128.22.5190.5190

Published: 2016

Journal Articles

The Devil Is Not As Black As He Is Painted - 3-Year Experience of Treating Newly Diagnosed CML Patients with Imatinib Generics

Vasily Shuvaev, MD, Mikhail Fominykh, MD, Vera Udaleva, MD, Irina I Zotova, MD, Regina Golovchenko, MD PhD, Dzhariyat Shikhbabaeva, MD, Irina Martynkevich, DSc, Lyudmila Martynenko, Marina Ivanova, MD PhD, Natalya Tsybakova, PhD, Ekaterina Motyko, PhD, Lyubov Polushkina, MD, Nadezhda Potikhonova, MD PhD, Sophya Tyranova, MD PhD, Marina Zenina, MD PhD, Kudrat Abdulkadyrov, MD PhD

Blood (2016) 128 (22): 5441.

https://doi.org/10.1182/blood.V128.22.5441.5441

Published: 2016

Journal Articles

Title: Progression-Free Survival 2 in Hematological Cancer Treatment Choices: Challenges to Routine Use

Angela Solaman, MHEcon, Andrew Walker, PhD, Faith E Davies, MD

Blood (2016) 128 (22): 5982.

https://doi.org/10.1182/blood.V128.22.5982.5982

Published: 2016

NARROW

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Preliminary Exploration of Patient Perspectives on Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia

The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies

Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma

A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety

Evaluating Isatuximab Interference with Monoclonal Protein Detection By Immuno-Capture and Liquid Chromatography Coupled to High Resolution Mass Spectrometry in the Pivotal Phase 3 Multiple Myeloma Trial, Icaria-MM

Potential Overuse of Primary Thromboprophylaxis in Medical Inpatients at Low Risk of Venous Thromboembolism

Geriatric Assessment (GA) Measures and Patient-Reported Outcomes (PROs) Among Older Adults Treated in a Phase 1b Study for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Inotuzumab Ozogamicin Compassionate Use for French Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Economic Impact of Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Compared to Conventional Recombinant Factor VIII (rFVIII)

A Patient-Centred Approach to Understanding the Trade-Offs Associated with Treatment Decision Making in Hematological Cancers with Short Life Expectancy

Obinutuzumab for CLL Relapsed and Refractory Patients When New Oral Drugs an Not Available

Impact on Quality of Life (QoL) of Patients with Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Under Ibrutinib Treatment: Preliminary Data from a Real World Prospective Project (pilot study)

Patient Perspectives on Symptom Experience and Impact on Health-Related Quality of Life in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia

Kinetics of T-Cell Subset Reconstitution Following Bendamustine-Containing Therapy for Low-Grade Lymphoproliferative Disease; A Population Based Analysis

Novel Lineage Depletion and Manufacturing Allows for Unprecedented Preservation of Autologous Blood Stem Cells for Gene Therapy of Fanconi Anemia Complementation Group Α

Laboratory-Developed MLPA ® Probes Enable CNV Detection in the CFHR4 Gene to Aid aHUS Genetic Evaluation

Safety and Efficacy of Blinatumomab Used in Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Treated in French Hematological Centers

The Devil Is Not As Black As He Is Painted - 3-Year Experience of Treating Newly Diagnosed CML Patients with Imatinib Generics

Title: Progression-Free Survival 2 in Hematological Cancer Treatment Choices: Challenges to Routine Use

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only